Cipla has signed a binding agreement with Pulmatrix Inc for co-development and licensing opportunity for a new asthma drug under development for an upfront consideration of $ 22 million, the domestic pharma major has revealed.

It has been signed between, Cipla Technologies LLC, the Cipla’s wholly-owned subsidiary in the US, with Pulmatrix Inc for an investment in phase 2 ready Pulmazole (inhaled ltraconazole), an inhaled anti-fungal formulation of itraconazole aimed at treating allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.

Also read: Cipla partners MannKind to sale Afrezza in India 

“Entry into a definitive agreement is contingent upon Pulmatrix raising additional funds from the market,” Cipla stated.

Upon signing the definitive agreement, the co-development cost towards development and the total free cash flow in relation to commercialisation of Pulmazole will be further shared by both the parties in a phased manner, Cipla stated.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!